Experiment Overview
| Repository ID: | FR-FCM-Z586 | Experiment name: | Venetoclax treatment in CLL patients has limited impact on circulating T and NK cells | MIFlowCyt score: | 83.75% |
| Primary researcher: | Charis Teh | PI/manager: | Charis Teh | Uploaded by: | Charis Teh |
| Experiment dates: | 2017-04-01 - 2022-04-30 | Dataset uploaded: | Apr 2022 | Last updated: | May 2022 |
| Keywords: | [CLL] [T cells] [venetoclax] | Manuscripts: | |||
| Organizations: |
The Walter and Eliza Hall Institute of Medical Research, Immunology, Melbourne, VIC3052 (Australia)
|
||||
| Purpose: | o profile circulating blood cells from CLL patients before and after treatment with venetoclax using flow cytometry | ||||
| Conclusion: | Venetoclax has minimal impact on circulating T or NK cells | ||||
| Comments: | None | ||||
| Funding: | This work was supported by: an Australian NHMRC Fellowships 1089072 (C.E.T), 1090236 and 1158024 (D.H.D.G), 1078730 and 1175960 (G.J.L); a Fulbright Australia-America Postdoctoral Fellowship (C.E.T); a Victorian Cancer Agency Mid-Career Fellowship MCRF20026 (C.E.T); Cancer Council of Victoria Grants-in-Aid 1146518 and 1102104 (D.H.D.G); Perpetual Impact Philanthropy Founding (C.E.T.); Australian NHRMC grants 2002618 (C.E.T), 1113577, 1016701, 1079560 (A.W.R/D.C.S.H); 1113133, 1153049 (G.J.L), the Metcalf Family (A.H.W); the Leukemia and Lymphoma Society, US, Specialized Center of Research [SCOR] grant 7015-18 (A.H.W); a Medical Research Future Fund grant 1141460 (A.H.W.); National Breast Cancer Foundation Australia IIRS-19-004; Breast Cancer Research Foundation (BCRF-20-182) (G.J.L), Investigator Initiated Study support from AbbVie and Genentech (Roche) for the mBEP study (ACTRN12615000702516) (G.J.L). | ||||
| Quality control: | - An anchor healthy blood sample is used in each run - All antibodies were titrated to determine ideal concentrations of used - Where samples needed to be ran in two batches on different days, cytometers with the same settings were used. | ||||
Experiment variables
| Conditions | |
|---|---|
| · pre-venetoclax | CLL_12_01.fcs · CLL_13_02.fcs · CLL_15_02.fcs · CLL_16_01.fcs · CLL_18_01.fcs · CLL_19_01.fcs · CLL_20_02.fcs · CLL_21_01.fcs · CLL_22_02.fcs · CLL_25_01.fcs · CLL_27_01.fcs · CLL_28_01.fcs · CLL_30_01 .fcs · CLL_31_01.fcs · CLL_33_01.fcs · CLL_35.fcs · CLL_36_01.fcs · CLL_37_01.fcs · CLL_39_01.fcs |
| · post-venetoclax | CLL_12_02.fcs · CLL_13_05.fcs · CLL_15_06.fcs · CLL_16_06.fcs · CLL_18_05.fcs · CLL_19_05.fcs · CLL_20_06.fcs · CLL_21_05.fcs · CLL_22_08.fcs · CLL_25_06.fcs · CLL_27_05.fcs · CLL_28_05.fcs · CLL_30_05.fcs · CLL_31_04.fcs · CLL_33_05.fcs · CLL_35_03.fcs · CLL_36_04.fcs · CLL_37_04.fcs · CLL_39_05.fcs |
